C
BioSyent Inc.
RX.V
TSX
C
Hold
5/28/2021Upgraded
BioSyent Inc. (RX.V) was upgraded to C from C- on 5/28/2021 due to a large increase in the growth index, valuation index and efficiency index. Earnings per share increased from $0.0379 to $0.1027, net income increased 157.43% from $510.7 to $1.31M, and EBIT increased 134.42% from $754.4 to $1.77M.
BioSyent Inc. (RX.V) was upgraded to C from C- on 5/28/2021 due to a large increase in the growth index, valuation index and efficiency index. Earnings per share increased from $0.0379 to $0.1027, net income increased 157.43% from $510.7 to $1.31M, and EBIT increased 134.42% from $754.4 to $1.77M.
C
Hold
5/24/2021Downgrade
BioSyent Inc. (RX.V) was downgraded to C- from C on 5/24/2021 due to a significant decline in the growth index, valuation index and volatility index. Earnings per share declined from $0.0525 to $0.0379, EBIT declined 19.22% from $933.9 to $754.4, and operating cash flow declined 0.98% from $1.55M to $1.54M.
BioSyent Inc. (RX.V) was downgraded to C- from C on 5/24/2021 due to a significant decline in the growth index, valuation index and volatility index. Earnings per share declined from $0.0525 to $0.0379, EBIT declined 19.22% from $933.9 to $754.4, and operating cash flow declined 0.98% from $1.55M to $1.54M.
C
Hold
9/8/2020Upgraded
BioSyent Inc. (RX.V) was upgraded to C from C- on 9/8/2020 due to an increase in the volatility index, growth index and total return index. Operating cash flow increased 286.97% from $420.5 to $1.63M.
BioSyent Inc. (RX.V) was upgraded to C from C- on 9/8/2020 due to an increase in the volatility index, growth index and total return index. Operating cash flow increased 286.97% from $420.5 to $1.63M.
C
Hold
8/13/2020Upgraded
BioSyent Inc. (RX.V) was upgraded to C- from D+ on 8/13/2020 due to an increase in the volatility index and efficiency index. Net income increased 22.1% from $884.8 to $1.08M.
BioSyent Inc. (RX.V) was upgraded to C- from D+ on 8/13/2020 due to an increase in the volatility index and efficiency index. Net income increased 22.1% from $884.8 to $1.08M.
D
Sell
2/12/2020Downgrade
BioSyent Inc. (RX.V) was downgraded to D+ from C- on 2/12/2020 due to a decline in the volatility index and efficiency index.
BioSyent Inc. (RX.V) was downgraded to D+ from C- on 2/12/2020 due to a decline in the volatility index and efficiency index.
C
Hold
11/15/2019Upgraded
BioSyent Inc. (RX.V) was upgraded to C- from D+ on 11/15/2019 due to an increase in the valuation index, total return index and volatility index.
BioSyent Inc. (RX.V) was upgraded to C- from D+ on 11/15/2019 due to an increase in the valuation index, total return index and volatility index.
D
Sell
10/29/2019Downgrade
BioSyent Inc. (RX.V) was downgraded to D+ from C- on 10/29/2019 due to a decline in the total return index and volatility index.
BioSyent Inc. (RX.V) was downgraded to D+ from C- on 10/29/2019 due to a decline in the total return index and volatility index.
C
Hold
10/10/2019Upgraded
BioSyent Inc. (RX.V) was upgraded to C- from D+ on 10/10/2019 due to an increase in the volatility index.
BioSyent Inc. (RX.V) was upgraded to C- from D+ on 10/10/2019 due to an increase in the volatility index.
D
Sell
9/11/2019Downgrade
BioSyent Inc. (RX.V) was downgraded to D+ from C- on 9/11/2019 due to a decline in the total return index, valuation index and volatility index.
BioSyent Inc. (RX.V) was downgraded to D+ from C- on 9/11/2019 due to a decline in the total return index, valuation index and volatility index.
C
Hold
6/17/2019Downgrade
BioSyent Inc. (RX.V) was downgraded to C- from C on 6/17/2019 due to a major decline in the growth index, volatility index and total return index. Operating cash flow declined 108.85% from $2.05M to -$181.8, EBIT declined 44.45% from $1.56M to $869.3, and earnings per share declined from $0.0833 to $0.0512.
BioSyent Inc. (RX.V) was downgraded to C- from C on 6/17/2019 due to a major decline in the growth index, volatility index and total return index. Operating cash flow declined 108.85% from $2.05M to -$181.8, EBIT declined 44.45% from $1.56M to $869.3, and earnings per share declined from $0.0833 to $0.0512.
C
Hold
1/18/2019Downgrade
BioSyent Inc. (RX.V) was downgraded to C from C+ on 1/18/2019 due to a noticeable decline in the volatility index and valuation index.
BioSyent Inc. (RX.V) was downgraded to C from C+ on 1/18/2019 due to a noticeable decline in the volatility index and valuation index.
C
Hold
12/4/2018Upgraded
BioSyent Inc. (RX.V) was upgraded to C+ from C on 12/4/2018 due to a noticeable increase in the valuation index, volatility index and solvency index. The quick ratio increased from 8.51 to 10.12.
BioSyent Inc. (RX.V) was upgraded to C+ from C on 12/4/2018 due to a noticeable increase in the valuation index, volatility index and solvency index. The quick ratio increased from 8.51 to 10.12.
C
Hold
9/8/2017Downgrade
BioSyent Inc. (RX.V) was downgraded to C from B- on 9/8/2017 due to a decline in the total return index.
BioSyent Inc. (RX.V) was downgraded to C from B- on 9/8/2017 due to a decline in the total return index.
B
Buy
7/28/2017Upgraded
BioSyent Inc. (RX.V) was upgraded to B- from C+ on 7/28/2017 due to an increase in the total return index, volatility index and solvency index. The quick ratio increased from 6.65 to 8.16.
BioSyent Inc. (RX.V) was upgraded to B- from C+ on 7/28/2017 due to an increase in the total return index, volatility index and solvency index. The quick ratio increased from 6.65 to 8.16.
C
Hold
5/16/2017Upgraded
BioSyent Inc. (RX.V) was upgraded to C+ from C on 5/16/2017 due to an increase in the total return index.
BioSyent Inc. (RX.V) was upgraded to C+ from C on 5/16/2017 due to an increase in the total return index.
C
Hold
5/1/2017Downgrade
BioSyent Inc. (RX.V) was downgraded to C from C+ on 5/1/2017 due to a decline in the volatility index and total return index.
BioSyent Inc. (RX.V) was downgraded to C from C+ on 5/1/2017 due to a decline in the volatility index and total return index.
C
Hold
1/30/2017Upgraded
BioSyent Inc. (RX.V) was upgraded to C+ from C on 1/30/2017 due to an increase in the valuation index and solvency index. The quick ratio increased from 6.23 to 8.35.
BioSyent Inc. (RX.V) was upgraded to C+ from C on 1/30/2017 due to an increase in the valuation index and solvency index. The quick ratio increased from 6.23 to 8.35.
C
Hold
9/29/2016Downgrade
BioSyent Inc. (RX.V) was downgraded to C from B on 9/29/2016 due to a decline in the valuation index.
BioSyent Inc. (RX.V) was downgraded to C from B on 9/29/2016 due to a decline in the valuation index.
B
Buy
9/27/2016Upgraded
BioSyent Inc. (RX.V) was upgraded to B from C on 9/27/2016 due to an increase in the volatility index.
BioSyent Inc. (RX.V) was upgraded to B from C on 9/27/2016 due to an increase in the volatility index.
C
Hold
9/15/2016Downgrade
BioSyent Inc. (RX.V) was downgraded to C from B on 9/15/2016 due to a decline in the valuation index.
BioSyent Inc. (RX.V) was downgraded to C from B on 9/15/2016 due to a decline in the valuation index.
B
Buy
9/13/2016Upgraded
BioSyent Inc. (RX.V) was upgraded to B from C on 9/13/2016 due to an increase in the volatility index.
BioSyent Inc. (RX.V) was upgraded to B from C on 9/13/2016 due to an increase in the volatility index.
C
Hold
9/7/2016Downgrade
BioSyent Inc. (RX.V) was downgraded to C from B on 09/07/2016.
BioSyent Inc. (RX.V) was downgraded to C from B on 09/07/2016.
B
Buy
8/15/2016Upgraded
BioSyent Inc. (RX.V) was upgraded to B from B- on 8/15/2016 due to a noticeable increase in the growth index, total return index and valuation index. Operating cash flow increased 519.15% from -$231.9 to $972, total revenue increased 23.34% from $2.75M to $3.39M, and EBIT increased 16.33% from $908.3 to $1.06M.
BioSyent Inc. (RX.V) was upgraded to B from B- on 8/15/2016 due to a noticeable increase in the growth index, total return index and valuation index. Operating cash flow increased 519.15% from -$231.9 to $972, total revenue increased 23.34% from $2.75M to $3.39M, and EBIT increased 16.33% from $908.3 to $1.06M.
B
Buy
8/11/2016Upgraded
BioSyent Inc. (RX.V) was upgraded to B- from C+ on 8/11/2016 due to a large increase in the total return index.
BioSyent Inc. (RX.V) was upgraded to B- from C+ on 8/11/2016 due to a large increase in the total return index.
C
Hold
8/3/2016Upgraded
BioSyent Inc. (RX.V) was upgraded to C+ from C on 8/3/2016 due to a major increase in the total return index, growth index and volatility index. Earnings per share increased from $0.0374 to $0.0495.
BioSyent Inc. (RX.V) was upgraded to C+ from C on 8/3/2016 due to a major increase in the total return index, growth index and volatility index. Earnings per share increased from $0.0374 to $0.0495.
C
Hold
4/14/2016Downgrade
BioSyent Inc. (RX.V) was downgraded to C from C+ on 4/14/2016 due to a decline in the valuation index.
BioSyent Inc. (RX.V) was downgraded to C from C+ on 4/14/2016 due to a decline in the valuation index.
C
Hold
3/30/2016Upgraded
BioSyent Inc. (RX.V) was upgraded to C+ from C on 3/30/2016 due to an increase in the volatility index.
BioSyent Inc. (RX.V) was upgraded to C+ from C on 3/30/2016 due to an increase in the volatility index.
C
Hold
3/11/2016Downgrade
BioSyent Inc. (RX.V) was downgraded to C from B on 3/11/2016 due to a significant decline in the volatility index, growth index and total return index. Earnings per share declined from $0.0611 to $0.0374, operating cash flow declined 26.5% from $1.41M to $1.04M, and EBIT declined 20.53% from $1.22M to $970.
BioSyent Inc. (RX.V) was downgraded to C from B on 3/11/2016 due to a significant decline in the volatility index, growth index and total return index. Earnings per share declined from $0.0611 to $0.0374, operating cash flow declined 26.5% from $1.41M to $1.04M, and EBIT declined 20.53% from $1.22M to $970.
B
Buy
1/15/2016Downgrade
BioSyent Inc. (RX.V) was downgraded to B from B+ on 1/15/2016 due to a large decline in the total return index.
BioSyent Inc. (RX.V) was downgraded to B from B+ on 1/15/2016 due to a large decline in the total return index.
B
Buy
12/31/2015Upgraded
BioSyent Inc. (RX.V) was upgraded to B+ from B on 12/31/2015 due to a large increase in the total return index, solvency index and volatility index. The quick ratio increased from 4.97 to 5.09.
BioSyent Inc. (RX.V) was upgraded to B+ from B on 12/31/2015 due to a large increase in the total return index, solvency index and volatility index. The quick ratio increased from 4.97 to 5.09.
B
Buy
8/24/2015Downgrade
BioSyent Inc. (RX.V) was downgraded to B from B+ on 8/24/2015 due to a decline in the total return index, valuation index and volatility index.
BioSyent Inc. (RX.V) was downgraded to B from B+ on 8/24/2015 due to a decline in the total return index, valuation index and volatility index.
B
Buy
7/27/2015Upgraded
BioSyent Inc. (RX.V) was upgraded to B+ from B on 7/27/2015 due to an increase in the valuation index.
BioSyent Inc. (RX.V) was upgraded to B+ from B on 7/27/2015 due to an increase in the valuation index.
B
Buy
6/4/2015Downgrade
BioSyent Inc. (RX.V) was downgraded to B from B+ on 6/4/2015 due to a substantial decline in the volatility index.
BioSyent Inc. (RX.V) was downgraded to B from B+ on 6/4/2015 due to a substantial decline in the volatility index.
B
Buy
5/20/2015Upgraded
BioSyent Inc. (RX.V) was upgraded to B+ from B on 5/20/2015 due to a large increase in the valuation index and solvency index. The quick ratio increased from 3.51 to 4.97.
BioSyent Inc. (RX.V) was upgraded to B+ from B on 5/20/2015 due to a large increase in the valuation index and solvency index. The quick ratio increased from 3.51 to 4.97.
B
Buy
2/17/2015Downgrade
BioSyent Inc. (RX.V) was downgraded to B from B+ on 2/17/2015 due to a major decline in the total return index.
BioSyent Inc. (RX.V) was downgraded to B from B+ on 2/17/2015 due to a major decline in the total return index.
B
Buy
10/7/2014Upgraded
BioSyent Inc. (RX.V) was upgraded to B+ from B on 10/7/2014 due to a noticeable increase in the total return index and valuation index.
BioSyent Inc. (RX.V) was upgraded to B+ from B on 10/7/2014 due to a noticeable increase in the total return index and valuation index.
B
Buy
9/16/2014Downgrade
BioSyent Inc. (RX.V) was downgraded to B from B+ on 9/16/2014 due to a noticeable decline in the total return index and valuation index.
BioSyent Inc. (RX.V) was downgraded to B from B+ on 9/16/2014 due to a noticeable decline in the total return index and valuation index.
B
Buy
9/8/2014Downgrade
BioSyent Inc. (RX.V) was downgraded to B+ from A- on 9/8/2014 due to a decline in the valuation index.
BioSyent Inc. (RX.V) was downgraded to B+ from A- on 9/8/2014 due to a decline in the valuation index.
A
Buy
8/22/2014Upgraded
BioSyent Inc. (RX.V) was upgraded to A- from B on 8/22/2014 due to a noticeable increase in the growth index, valuation index and solvency index. EBIT increased 79.64% from $612.5 to $1.1M, earnings per share increased from $0.034 to $0.055, and total revenue increased 26.96% from $2.22M to $2.82M.
BioSyent Inc. (RX.V) was upgraded to A- from B on 8/22/2014 due to a noticeable increase in the growth index, valuation index and solvency index. EBIT increased 79.64% from $612.5 to $1.1M, earnings per share increased from $0.034 to $0.055, and total revenue increased 26.96% from $2.22M to $2.82M.
B
Buy
8/1/2014Downgrade
BioSyent Inc. (RX.V) was downgraded to B from B+ on 8/1/2014 due to a decline in the total return index and valuation index.
BioSyent Inc. (RX.V) was downgraded to B from B+ on 8/1/2014 due to a decline in the total return index and valuation index.
B
Buy
6/16/2014Upgraded
BioSyent Inc. (RX.V) was upgraded to B+ from B on 6/16/2014 due to a major increase in the total return index.
BioSyent Inc. (RX.V) was upgraded to B+ from B on 6/16/2014 due to a major increase in the total return index.
B
Buy
5/27/2014Downgrade
BioSyent Inc. (RX.V) was downgraded to B from A- on 5/27/2014 due to a decline in the valuation index.
BioSyent Inc. (RX.V) was downgraded to B from A- on 5/27/2014 due to a decline in the valuation index.
A
Buy
5/23/2014Upgraded
BioSyent Inc. (RX.V) was upgraded to A- from B on 5/23/2014 due to an increase in the valuation index and solvency index. The quick ratio increased from 4.07 to 5.45.
BioSyent Inc. (RX.V) was upgraded to A- from B on 5/23/2014 due to an increase in the valuation index and solvency index. The quick ratio increased from 4.07 to 5.45.
B
Buy
3/21/2014Downgrade
BioSyent Inc. (RX.V) was downgraded to B from B+ on 3/21/2014 due to a decline in the valuation index.
BioSyent Inc. (RX.V) was downgraded to B from B+ on 3/21/2014 due to a decline in the valuation index.
B
Buy
3/18/2014Downgrade
BioSyent Inc. (RX.V) was downgraded to B+ from A- on 3/18/2014 due to a major decline in the total return index, valuation index and growth index. EBIT declined 25.32% from $772.4 to $576.8, total revenue declined 8.88% from $2.24M to $2.04M, and earnings per share declined from $0.0385 to $0.0384.
BioSyent Inc. (RX.V) was downgraded to B+ from A- on 3/18/2014 due to a major decline in the total return index, valuation index and growth index. EBIT declined 25.32% from $772.4 to $576.8, total revenue declined 8.88% from $2.24M to $2.04M, and earnings per share declined from $0.0385 to $0.0384.
